Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia
Open Access
- 19 May 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 815
Abstract
Hyperviscosity syndrome is a serious complication associated with high levels of paraproteins in patients with hematological malignancies. Therapeutic advances in disease control may reduce the incidence of hyperviscosity syndrome; however, management of acute cases requires an understanding of key symptoms and prompt treatment to mitigate serious consequences.Keywords
This publication has 37 references indexed in Scilit:
- Evidence-based focused review of management of hyperviscosity syndromeBlood, 2012
- Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) GuidelinesMayo Clinic Proceedings, 2010
- Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemiaAnnals of Oncology, 2004
- Hyperviscosity Syndrome in Plasma Cell DyscrasiasSeminars in Thrombosis and Hemostasis, 2003
- Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 casesBritish Journal of Haematology, 2001
- The Hyperviscosity SyndromesSeminars in Thrombosis and Hemostasis, 1999
- Changing clinical presentation of multiple myelomaEuropean Journal of Cancer and Clinical Oncology, 1991
- Human Immunoglobulin G and Immunoglobulin G Subclasses: Biochemical, Genetic, and Clinical AspectsCritical Reviews in Clinical Laboratory Sciences, 1989
- Evaluation of hyperviscosity in monoclonal gammopathiesThe American Journal of Medicine, 1985
- Aggregation of γG3 proteins: relevance to the hyperviscosity syndromeJournal of Clinical Investigation, 1970